Focus: Penumbra is a public medical device company specializing in minimally-invasive vascular and surgical devices for acute stroke, pulmonary embolism, and intracranial hemorrhage. The company operates at ~$1.1B in FY2025 revenue with strong recent growth and profitability.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Stable — net -1 jobs in 30d
29 added, 30 removed. Backfill posture.
Best suited for commercial, operational, and manufacturing professionals seeking growth in a profitable, acquisition-target medical device company; limited appeal for pure research scientists.
Help build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Penumbra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - PR Newswire
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT PR Newswire
Penumbra’s FDA nod for clot removal tech a win for Boston Scientific - MedTech Dive
Penumbra’s FDA nod for clot removal tech a win for Boston Scientific MedTech Dive
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke - Medical Device Network
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke Medical Device Network
FDA OKs Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy for Stroke - Medical Product Outsourcing
FDA OKs Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy for Stroke Medical Product Outsourcing
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke - BioSpace
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke BioSpace
GSK Acquires Nuvalon for $10.6 Billion to Boost Cancer Drug Pipeline - News and Statistics - IndexBox
GSK Acquires Nuvalon for $10.6 Billion to Boost Cancer Drug Pipeline - News and Statistics IndexBox
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo